loading page

Medication Therapy of High-Dose Methotrexate: An Evidence-Based Practice Guideline Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society
  • +39
  • Song Zaiwei,
  • Yang Hu,
  • Shuang Liu,
  • Guanru Wang,
  • Suo-Di Zhai,
  • Xianglin Zhang,
  • Youping Li,
  • Guanhua Du,
  • Yuankai Shi,
  • Yaolong Chen,
  • Mei Dong,
  • Guo Rui-chen,
  • Wei Guo,
  • Hongbing Huang,
  • Xiaojun Huang,
  • Hongmei Jing,
  • Xiaoyan Ke,
  • Guohui Li,
  • Liyan Miao,
  • Xiaohui Niu,
  • Feng Qiu,
  • Jingnan Shen,
  • Jingyan Tang,
  • Tian-You Wang,
  • Xiaoling Wang,
  • Zhuo Wang,
  • Jiuhong Wu,
  • Si-Yan Zhan,
  • Bi-kui Zhang,
  • Lingli Zhang,
  • Yanhua Zhang,
  • Wei Zhang,
  • Li Zhao,
  • Li-bo Zhao,
  • Jiancun Zhen,
  • Huyong Zheng,
  • Zhu Zhu,
  • Dan Jiang,
  • Zhencheng Huang,
  • Zhiyuan Tan,
  • Qiaonan Lin,
  • Rongsheng Zhao
Song Zaiwei
Peking University Third Hospital

Corresponding Author:[email protected]

Author Profile
Yang Hu
Peking University Third Hospital
Author Profile
Shuang Liu
Peking University Third Hospital
Author Profile
Guanru Wang
Peking University Third Hospital
Author Profile
Suo-Di Zhai
Peking University Third Hospital
Author Profile
Xianglin Zhang
China-Japan Friendship Hospital
Author Profile
Youping Li
Sichuan University West China Hospital
Author Profile
Guanhua Du
Chinese Academy of Medical Sciences and Peking Union Medical College
Author Profile
Yuankai Shi
Chinese Academy of Medical Sciences and Peking Union Medical College
Author Profile
Yaolong Chen
Lanzhou University School of Basic Medical Sciences
Author Profile
Mei Dong
Harbin Medical University Third Hospital
Author Profile
Guo Rui-chen
Shandong University Qilu Hospital
Author Profile
Wei Guo
Peking University People's Hospital
Author Profile
Hongbing Huang
Sun Yat-sen University Cancer Center
Author Profile
Xiaojun Huang
Peking University People's Hospital
Author Profile
Hongmei Jing
Peking University Third Hospital
Author Profile
Xiaoyan Ke
Peking University Third Hospital
Author Profile
Guohui Li
Chinese Academy of Medical Sciences and Peking Union Medical College
Author Profile
Liyan Miao
First Affiliated Hospital of Soochow University
Author Profile
Xiaohui Niu
Beijing Jishuitan Hospital
Author Profile
Feng Qiu
The First Affiliated Hospital of Chongqing Medical University
Author Profile
Jingnan Shen
Sun Yat-sen University First Affiliated Hospital
Author Profile
Jingyan Tang
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
Author Profile
Tian-You Wang
Beijing Children's Hospital Capital Medical University
Author Profile
Xiaoling Wang
Beijing Children's Hospital Capital Medical University
Author Profile
Zhuo Wang
Changhai Hospital
Author Profile
Jiuhong Wu
The 306th Hospital of People's Liberation Army
Author Profile
Si-Yan Zhan
Peking University School of Public Health
Author Profile
Bi-kui Zhang
Second Xiangya Hospital
Author Profile
Lingli Zhang
Sichuan University West China Second University Hospital
Author Profile
Yanhua Zhang
Peking University Cancer Hospital
Author Profile
Wei Zhang
Jishuitan Hospital and Fourth Medical College of Peking University
Author Profile
Li Zhao
Shengjing hospital of China medical university
Author Profile
Li-bo Zhao
Beijing Children's Hospital Capital Medical University
Author Profile
Jiancun Zhen
Jishuitan Hospital and Fourth Medical College of Peking University
Author Profile
Huyong Zheng
Beijing Children's Hospital Capital Medical University
Author Profile
Zhu Zhu
Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,
Author Profile
Dan Jiang
Peking University Third Hospital
Author Profile
Zhencheng Huang
Peking University Third Hospital
Author Profile
Zhiyuan Tan
Peking University Third Hospital
Author Profile
Qiaonan Lin
Peking University Third Hospital
Author Profile
Rongsheng Zhao
Peking University Third Hospital
Author Profile

Abstract

Objectives: A lot of medication risks related to high-dose methotrexate (HDMTX) therapy still remain to be identified and standardized. This study aims to establish an evidence-based practice guideline for individualized medication of HDMTX. Methods: The practice guideline was launched by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. The guideline was developed following the WHO handbook for guideline development and the methodology of evidence-based medicine (EBM). The guideline was initially registered in the International Practice Guidelines Registry Platform (IPGRP-2017CN021). Systematic reviews were conducted to synthesis available evidence. A multicenter cross-sectional study was conducted by questionnaires to evaluate patients’ perception and willingness on individualized medication of HDMTX. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to rate the quality of evidence and to grade the strength of recommendations. Results: Multidisciplinary working groups were included in this guideline, including clinicians, pharmacists, methodologists, pharmacologists and pharmacoeconomic specialists. A total of 124 patients were involved to integrate patient values and preferences. Finally, the guideline presents 28 recommendations, regarding evaluation prior to medication (renal function, liver function, pleural effusion, comedications, genetic testing), pre-treatment and routine dosing regimen, therapeutic drug monitoring (necessity, method, timing, target concentration), leucovorin rescue (initial timing, dosage regimen and optimization), management of toxicities. Of them, 12 are strong recommendations. Conclusions: We developed an evidence-based practice guideline with respect to HDMTX medication using a rigorous and multidisciplinary approach. This guideline provides comprehensive and practical recommendations involving the whole process of HDMTX medication to health care providers.
17 May 2021Submitted to British Journal of Clinical Pharmacology
21 May 2021Submission Checks Completed
21 May 2021Assigned to Editor
03 Jun 2021Reviewer(s) Assigned
23 Jul 2021Review(s) Completed, Editorial Evaluation Pending
10 Aug 2021Editorial Decision: Revise Minor
22 Aug 20211st Revision Received
23 Aug 2021Submission Checks Completed
23 Aug 2021Assigned to Editor
23 Aug 2021Review(s) Completed, Editorial Evaluation Pending
16 Sep 2021Editorial Decision: Revise Minor
26 Sep 20212nd Revision Received
01 Oct 2021Submission Checks Completed
01 Oct 2021Assigned to Editor
01 Oct 2021Review(s) Completed, Editorial Evaluation Pending
15 Oct 2021Editorial Decision: Accept